Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268371 | 0.90 | PROKR1 (0.42) | PROKR1GRM5PDE4APDE4BPDE4C | |
| SCHEMBL1269328 | 0.90 | HTR6 (0.36) | GRM5HTR6PDE4APDE4BPDE4C | |
| SCHEMBL1269325 | 0.88 | SMN1; SMN2 (0.40) | GRM5HTR6PDE4APDE4BPDE4C | |
| SCHEMBL1269529 | 0.85 | PROKR1 (0.40) | PROKR1GRM5PDE4APDE4BPDE4C | |
| SCHEMBL1268804 | 0.85 | PROKR1 (0.36) | PROKR1GRM5HTR6PDE4APDE4B | |
| SCHEMBL1269350 | 0.83 | PROKR1 (0.38) | PROKR1HTR6TP53POLBLMNA | |
| SCHEMBL1268426 | 0.78 | LMNA (0.37) | TP53POLBLMNA | |
| SCHEMBL1268439 | 0.77 | TP53 (0.34) | TP53POLBLMNA | |
| SCHEMBL1269223 | 0.76 | HTR6 (0.41) | HTR6 | |
| SCHEMBL1269182 | 0.74 | TP53 (0.38) | TP53POLBLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | PROKR1 3668/4885GRM5 2287/4885HTR6 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.